Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiRNA profile of single hormone receptor positive breast cancer patients

ABSTRACT: miRNA profile of single hormone receptor positive breast cancer patients

PROVIDER: PRJNA649524 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

miRNA profile of single hormone receptor positive breast cancer patients

Project description:In the current pilot study we aimed to identify differentially expressed miRNAs in two types of single hormone receptor-positive breast cancer [ER(+)/PgR(-) and ER(-)/PgR(+)] with further distinction into HER2-overexpressing/amplified and HER2-negative tumors in a well-established cohort collected at Medical University of Gdańsk.

2020-08-15 | GSE155362 | GEO

Preoperative short-term hormone therapy for hormone receptor positive breast cancer

Project description:Core needle biopsy (Cx) primary cancer specimens were collected at Okayama University Hospital in Japan from hormone receptor positive /HER2 negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Thirty clinical TNM stage I and II women were enrolled in this study. The study was approved by the Institutional Review Board and all patients signed informed consent forms. Patients received preoperative hormone therapy daily for two weeks before surgery. Premenopausal patients received tamoxifen (40 mg) and postmenopausal patients received letrozole (2.5 mg). All patients underwent a mastectomy or breast-conserving surgery. Surgical samples after treatment were also collected. Hormone and HER2 receptor statuses were determined in the diagnostic Cx specimens before hormone therapy. Cases with ≥1% positive nuclear staining for estrogen receptors (ER) or progesterone receptors (PgR) with IHC were considered hormone receptor-positive. Cases with either 0 or 1 positive IHC staining for HER2 or with an HER2 gene copy number < 2.0 by fluorescent in situ hybridization (FISH) analysis were considered HER2−. Specimens for gene expression analysis were collected into RNA and later stored at -80°C. Gene expression profiling was performed using Affymetrix U133A gene chips. Expression data were normalized using the MAS5 algorithm, mean centered to 600, and log2 transformed before further analysis.

2017-04-19 | GSE80077 | GEO

RNA-seq analysis of hormone receptor positive breast cancer cell line UCD4 with 24h hormone treatment

Project description:RNA-seq analysis of hormone receptor positive breast cancer cell line UCD4 with 24h hormone treatment

| PRJNA807651 | ENA

RNA-seq analysis of hormone receptor positive breast cancer cell line T47D with 24h hormone treatment

Project description:RNA-seq analysis of hormone receptor positive breast cancer cell line T47D with 24h hormone treatment

| PRJNA807652 | ENA

Gene expression analysis of previously treated hormone receptor-positive metastatic breast cancer

Project description:Gene expression analysis of previously treated hormone receptor-positive metastatic breast cancer

| PRJNA527860 | ENA

Gene expression analysis of treatment-naïve hormone receptor-positive metastistic breast cancer

Project description:Gene expression analysis of treatment-naïve hormone receptor-positive metastistic breast cancer

| PRJNA551385 | ENA

Anti-cancer action of imidazopyridine BAG1 compounds in steriod hormone receptor-positive breast and prostate cancer

Project description:Transcriptomics analyses to study the effect of the imidazopyridine X15695 on proliferation of estrogen receptor positive (ER+) breast and androgen receptor positive (AR+) prostate cancer cells. The effect of X15695 was analyzed on vehicle or steroid hormone-treated breast and prostate cancer cells.

2023-03-13 | GSE218556 | GEO

Hyperactivation of PI3K promotes escape from hormone dependence in estrogen receptor-positive breast cancer

Project description:Hyperactivation of phosphatidylinositol-3 kinase (PI3K) promotes escape from hormone dependence in estrogen receptor-positive breast cancer. A significant fraction of breast cancers exhibit de novo or acquired resistance to estrogen deprivation. We used gene expression microarrays to identify genes and pathways that are commonly dysregulated in ER+ cell lines with acquired hormone-independent growth. MCF-7, ZR75-1, MDA-361, and HCC-1428 ER+, estrogen-responsive breast cancer cells were cultured under hormone-depleted conditions (10% DCC-FBS) for several months until sustainable hormone-independent cell populations emerged.

2010-06-15 | GSE19639 | GEO

Androgen receptor is a back-door inhibitor of Androgen Receptor is a Backdoor Inhibitor of Wildtype and Mutant Estrogen Receptors in Refractory Hormone Receptor-Positive Breast Cancers

Project description:HCI-13 patient-derived xenograft was treated with vehicle or a tissue-selective androgen receptor modulator (SARM), enobosarm. RNA was extracted from the tumors and microarray was performed. Objective: The objective of the study is to determine the effect of an androgen receptor (AR) agonist or a selective AR modulator (SARM) on hormone receptor-positive breast cancer growth in preclinical models and to determine the underlying mechanism of action.

2019-07-31 | GSE126318 | GEO

Androgen Receptor is a Backdoor Inhibitor of Wildtype and Mutant Estrogen Receptors in Refractory Hormone Receptor-Positive Breast Cancers

Project description:Androgen Receptor is a Backdoor Inhibitor of Wildtype and Mutant Estrogen Receptors in Refractory Hormone Receptor-Positive Breast Cancers

| PRJNA526053 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data